Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...

Some of Ascend Performance Materials Inc.’s creditors provided fresh financing to the troubled chemicals firm, giving it time ...

PPT Group, home to trusted brands including Alluris, James Heal, Lansmont, and Mecmesin, is pleased to announce its acquisition by SK Capital - a private investment firm with a disciplined focus on ...

HALIFAX, England-- ( BUSINESS WIRE )--Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the ...

Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital Partners. David Meek, former CEO of Mirati Therapeutics ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million. Bluebird on ...

As part of the agreement, Carlyle Group (NASDAQ:CG) and SK Capital will also provide bluebird (NASDAQ:BLUE) with primary capital to expand the commercial reach of its gene therapies targeted at ...

Carlyle and SK Capital will provide bluebird primary capital to scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral ...

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, completed the acquisition of ...